Genome-wide association studies of LRRK2 modifiers of Parkinson's disease
Dongbing LaiiD, Babak AlipanahiiD, Pierre FontanillasiD, Tae-Hwi Linus Schwantes-AniD, Jan Olav AaslyiD, Roy N. AlcalayiD, Gary W. BeechamiD, Daniela BergiD, Susan BressmaniD, Alexis BriceiD, Kathrin BrockmanniD, Lorraine N. ClarkiD, Mark CooksoniD, Sayantan DasiD, Vivianna M. Van DeerliniD, Jordan FollettiD, Matthew James FarreriD, Joanne TrinhiD, Thomas GasseriD, Stefano GoldwurmiD, Emil Karl GustavssoniD, Christine KleiniD, Anthony Edward LangiD, J. William Langston, Jeanne C. LatourelleiD, , Tatiana ForoudiD
Abstract
ObjectiveThe aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinsons disease. MethodsWe performed the first genome-wide association study of penetrance and age-at-onset of Parkinsons disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genome-wide association study of Parkinsons disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers. ResultsA variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; P-value=2.5E-08, beta=1.27, SE=0.23, risk allele: C) met genome-wide significance for the penetrance model. A region on chromosome 3, within a previously reported linkage peak for Parkinsons disease susceptibility, showed suggestive associations in both models (penetrance top variant: P-value=1.1E-07; age-at-onset top variant: P-value=9.3E-07). A polygenic risk score derived from publicly available Parkinsons disease summary statistics was a significant predictor of penetrance, but not of age-at-onset. InterpretationThis study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinsons disease associated variants collectively increase the penetrance of LRRK2 mutations.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 54
- FWCI
- 4.54
- Field percentile
- top 4%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Penetrance of Parkinson’s disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score
Hirotaka Iwaki, Cornelis Blauwendraat, … Andrew Singleton·Movement DisordersPeer-reviewed·Jan 20, 2020
- MDSGene update and expansion: Clinical and genetic spectrum of LRRK2 variants in Parkinson's disease
Clara Krüger, Shen‐Yang Lim, … Katja Lohmann·medRxiv·Dec 10, 2024
- Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity
An Phu Tran Nguyen, Roger Moser, … Darren J. Moore·Human Molecular GeneticsPeer-reviewed·Jan 1, 2026
- Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson disease
Mie Rizig, Oluwadamilola Omolara Ojo, … Njideka Ulunma Okubadejo·Neurobiology of AgingPeer-reviewed·Oct 1, 2020
- Genetic Modifiers of Pathogenic LRRK2 G2019S Neurodegeneration in Drosophila
Sierra Lavoy, Vinita G. Chittoor-Vinod, … Ian Martin·GeneticsPeer-reviewed·Jun 15, 2018
- Leucine Rich Repeat Kinase 2 (LRRK2) Gly2019Ser Mutation Is Absent In A Second Cohort Of Nigerian Africans With Parkinson Disease.
Njideka Ulunma Okubadejo, Mie Rizig, … Henry Houlden·PLoS ONEPeer-reviewed·Dec 3, 2018